EP4171623A4 - Effets de latence positive sur la prévention et le traitement de la coccidiose par l'intermédiaire d'aliments pour animaux - Google Patents

Effets de latence positive sur la prévention et le traitement de la coccidiose par l'intermédiaire d'aliments pour animaux Download PDF

Info

Publication number
EP4171623A4
EP4171623A4 EP21829178.9A EP21829178A EP4171623A4 EP 4171623 A4 EP4171623 A4 EP 4171623A4 EP 21829178 A EP21829178 A EP 21829178A EP 4171623 A4 EP4171623 A4 EP 4171623A4
Authority
EP
European Patent Office
Prior art keywords
coccidiosis
prevention
effects
treatment
animal feed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21829178.9A
Other languages
German (de)
English (en)
Other versions
EP4171623A2 (fr
Inventor
William P. PFUND
Amy E. STEFFEK
Andrew A. Dahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zivo Bioscience Inc
Original Assignee
Zivo Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zivo Bioscience Inc filed Critical Zivo Bioscience Inc
Priority claimed from PCT/US2021/039178 external-priority patent/WO2021263160A2/fr
Publication of EP4171623A2 publication Critical patent/EP4171623A2/fr
Publication of EP4171623A4 publication Critical patent/EP4171623A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Sustainable Development (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
EP21829178.9A 2020-06-26 2021-06-25 Effets de latence positive sur la prévention et le traitement de la coccidiose par l'intermédiaire d'aliments pour animaux Pending EP4171623A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063044770P 2020-06-26 2020-06-26
PCT/US2021/039178 WO2021263160A2 (fr) 2020-06-26 2021-06-25 Effets de latence positive sur la prévention et le traitement de la coccidiose par l'intermédiaire d'aliments pour animaux

Publications (2)

Publication Number Publication Date
EP4171623A2 EP4171623A2 (fr) 2023-05-03
EP4171623A4 true EP4171623A4 (fr) 2024-08-14

Family

ID=85727797

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21829178.9A Pending EP4171623A4 (fr) 2020-06-26 2021-06-25 Effets de latence positive sur la prévention et le traitement de la coccidiose par l'intermédiaire d'aliments pour animaux

Country Status (1)

Country Link
EP (1) EP4171623A4 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759241B1 (en) * 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
US9345756B2 (en) * 2012-03-22 2016-05-24 The Chemo-Sero-Therapeutic Research Institute LPS vaccine
WO2020132318A1 (fr) * 2018-12-21 2020-06-25 Zivo Bioscience, Inc. Ingrédient alimentaire algal pour contrôler les effets des coccidioses et des entérites nécrotiques chez les volailles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759241B1 (en) * 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
US9345756B2 (en) * 2012-03-22 2016-05-24 The Chemo-Sero-Therapeutic Research Institute LPS vaccine
WO2020132318A1 (fr) * 2018-12-21 2020-06-25 Zivo Bioscience, Inc. Ingrédient alimentaire algal pour contrôler les effets des coccidioses et des entérites nécrotiques chez les volailles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Lipopolysaccharide", WIKIPEDIA, 31 December 2019 (2019-12-31), XP055879053, Retrieved from the Internet <URL:https://en.wikipedia.org/w/index.php?title=Lipopolysaccharide&oldid=933419780> [retrieved on 20220114] *
MOLTENI MONICA ET AL: "Natural Products with Toll-Like Receptor 4 Antagonist Activity", vol. 2018, 1 January 2018 (2018-01-01), pages 1 - 9, XP093135080, ISSN: 2090-8040, Retrieved from the Internet <URL:http://downloads.hindawi.com/journals/iji/2018/2859135.xml> DOI: 10.1155/2018/2859135 *
R LEVINE ET AL: "Evaluation of the effects of feeding dried algae containing beta-1,3-glucan on broilers challenged with Eimeria", POULTRY SCIENCE, vol. 97, no. 10, 1 October 2018 (2018-10-01), Oxford, pages 3494 - 3500, XP055722067, ISSN: 0032-5791, DOI: 10.3382/ps/pey227 *
ZHOU ZUOYONG ET AL: "Upregulation of chicken TLR4, TLR15 and MyD88 in heterophils and monocyte-derived macrophages stimulated with Eimeria tenella in vitro", EXPERIMENTAL PARASITOLOGY, vol. 133, no. 4, 1 April 2013 (2013-04-01), US, pages 427 - 433, XP093135218, ISSN: 0014-4894, DOI: 10.1016/j.exppara.2013.01.002 *

Also Published As

Publication number Publication date
EP4171623A2 (fr) 2023-05-03

Similar Documents

Publication Publication Date Title
EP4267582A4 (fr) Méthodes et nucléosides modifiés pour le traitement d&#39;infections à coronavirus
EP3837359A4 (fr) Méthodes et compositions pour le traitement d&#39;une maladie mitochondriale ou de troubles mitochondriaux et hétéroplasmie
EP3723513A4 (fr) Probiotiques et métabolites de fermentation pour la prévention et le traitement d&#39;états pathologiques chez des animaux
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3765611A4 (fr) Oligonucléotides ciblant la pcsk9 pour le traitement de l&#39;hypercholestérolémie et d&#39;états apparentés
MA52861A (fr) Méthodes et compositions pour le traitement de l&#39;apnée du sommeil
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3762505A4 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3409136A4 (fr) Dispositif pour le traitement de l&#39;arthrite et de l&#39;arthrose des extrémités, des inflammations chroniques, et pour la réduction de la douleur et de la tension musculaire
EP4138906A4 (fr) Méthodes pour la prophylaxie et le traitement de la covid et de la covid-19
EP3639833A4 (fr) Agent pour la prévention ou le traitement de maladies liées à la graisse et/ou de l&#39;inflammation
EP3664795A4 (fr) Cannabis et ses dérivés pour le traitement de la douleur et de l&#39;inflammation associées à la pulpe dentaire et de la régénération osseuse associée à des défauts osseux de la mâchoire
MA51056A (fr) Compositions et méthodes pour le traitement d&#39;affections métaboliques
EP3801489A4 (fr) Agents actifs acylés et leurs procédés d&#39;utilisation pour le traitement de troubles auto-immuns
EP3952881A4 (fr) Compositions et procédés pour le traitement d&#39;inconfort des lentilles de contact
MA55497A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
EP3781584A4 (fr) Promédicaments de 4&#39;-thio-nucléotide et de nucléoside pour le traitement du cancer
EP4114422A4 (fr) Compositions et méthodes pour le traitement d&#39;infections bactériennes intracellulaires
EP3870154A4 (fr) Compositions et méthodes de prévention et de traitement de pathologies induites par des antibiotiques à l&#39;aide de probiotiques à l&#39;état de biofilm
EP3966320A4 (fr) Traitement et détection de neuropathies héréditaires et de troubles associés
EP3978009A4 (fr) Fluctuation d&#39;ordonnances en médecine traditionnelle chinoise pour la prévention/traitement du syndrome métabolique et de ses complications
EP4073060A4 (fr) Inhibiteurs de l&#39;histone déméthylase spécifique de la lysine pour le traitement de néoplasmes myéloprolifératifs
EP4157341A4 (fr) Peptides pour la prévention et le traitement de la covid-19
EP3570835A4 (fr) Méthodes et compositions pharmaceutiques pour la prévention ou le traitement d&#39;affections dermiques immuno-inflammatoires

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240711

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/02 20060101ALI20240705BHEP

Ipc: A61P 33/02 20060101ALI20240705BHEP

Ipc: A61K 39/39 20060101ALI20240705BHEP

Ipc: A61K 36/00 20060101ALI20240705BHEP

Ipc: A23K 50/00 20160101ALI20240705BHEP

Ipc: A23K 10/00 20160101ALI20240705BHEP

Ipc: A61K 39/00 20060101ALI20240705BHEP

Ipc: A61P 37/04 20060101ALI20240705BHEP

Ipc: A61K 39/012 20060101AFI20240705BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS